US5588681057
US5588681057
Madrigal Pharmaceuticals, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 958.403.000 | 180.133.000 | 432.1% |
| Cost of Revenue | 56.148.000 | 6.233.000 | 800.8% |
| Gross Profit | 902.255.000 | 173.900.000 | 418.8% |
| 1.202.352.000 | 671.775.000 | 79.0% | |
| Operating Income | -300.097.000 | -497.875.000 | 39.7% |
| Pretax Income | -288.284.000 | -465.892.000 | 38.1% |
| Net Income Common Stockholders | -288.284.000 | -465.892.000 | 38.1% |
| -- | -- | -- | |
| -- | -- | -- |